MedPath

Mersana Therapeutics Stock Drops Following Phase 1 Trial Data Release

7 months ago2 min read
On Friday, Mersana Therapeutics Inc. (MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin (Emi-Le). The drug was generally well tolerated, with no Grade 4 or 5 treatment-related adverse events reported. At intermediate doses (38.1 mg/m2 to 67.4 mg/m2), the confirmed objective response rate (ORR) among evaluable patients was 23% across all B7-H4 high tumors and 23% with B7-H4 high triple-negative breast cancer (TNBC). These patients had previously been treated with at least one topo-1 ADC.
In comparison, the ORR with standard-of-care single-agent chemotherapy in relapsed/refractory TNBC was approximately 5%, with progression-free survival of approximately seven weeks in the ASCENT Phase 3 trial of sacituzumab govitecan. Encouraged by these results, Mersana has advanced a dose of 67.4 mg/m2 every four weeks into an expansion cohort in patients with TNBC who have received one to four prior treatment lines.
At high doses above 76 mg/m2, the confirmed ORR among evaluable patients was 22% across all B7-H4 high tumors, with 78% of patients experiencing a ≥30% tumor reduction in target lesions. However, objective responses in multiple evaluable patients with B7-H4 high tumors were not confirmed after protocol-mandated dose delays for proteinuria. Mersana is implementing proteinuria mitigation efforts and continues to examine higher doses in dose escalation and backfill cohorts to identify a second dose for the expansion portion of the trial.
Concurrently, the FDA granted an additional Fast Track designation to Mersana Therapeutics’ XMT-1660 for advanced or metastatic breast cancer in patients with HER2 low or HER2-negative disease, including TNBC, who have received a prior topoisomerase-1 inhibitor ADC. Hormone-receptor positive patients should also have received or be ineligible for endocrine therapy. The World Health Organization has approved emiltatug ledadotin (abbreviated as Emi-Le) as XMT-1660’s international nonproprietary name.
Despite these developments, Mersana Therapeutics' stock price dropped by 36.6% to $0.8245 at last check on Friday.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.